Drugs / HRS-9821
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07567872 | Jul → Sep 2026 expected | chronic obstructive pulmonary disease | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT07116915 | Aug 2025 → Dec 2026 expected | chronic obstructive pulmonary disease | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT05622864 | Jan 2023 → May 2025 | chronic obstructive pulmonary disease | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07640451 | Jun → Oct 2026 expected | chronic obstructive pulmonary disease | Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-9821 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07640451 ↗ |
| Route | Inhaled | “Nebulized Inhalation of HRS-9821 Suspension” NCT05622864 ↗ |